ROSEN, LEADING INVESTOR COUNSEL, Encourages Li Auto Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action with an Expanded Class Period “ LI

NEW YORK, June 14, 2024 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights…

Senvest Capital Inc. Announces Voting Results from its 2024 Annual Meeting of Shareholders By Investing.com

MONTREAL, June 14, 2024 (GLOBE NEWSWIRE) — Senvest Capital Inc. (the Corporation) (TSX: SEC) is pleased…

Israeli jets strike targets in Lebanon after missile barrage hits northern areas By Reuters

By James Mackenzie JERUSALEM (Reuters) -Israeli jets and artillery hit targets in southern Lebanon on Friday…

Argenx stock gets H.C. Wainwright nod on Vyvgart growth and pipeline progress By Investing.com

On Friday, H.C. Wainwright reaffirmed a Buy rating for the biopharmaceutical company argenx SE (NASDAQ: ARGX)…

Bank of America stock upgraded at KBW on strong fundamentals; price target raised By Investing.com

On Friday, Keefe, Bruyette & Woods shifted their position on Bank of America shares (NYSE:BAC), raising…

Westlate Chemical shares ‘current valuation fair’ says RBC Capital By Investing.com

On Friday, RBC Capital maintained a Sector Perform rating on Westlake Chemical Corporation (NYSE:) with a…

Evercore ISI sets fresh target on AZZ Inc shares, cites transformation By Investing.com

On Friday, Evercore ISI initiated coverage on AZZ Inc . (NYSE:) shares, a galvanized steel and…

ASX shares target reduced by UBS, highlights competitive threats By Investing.com

On Friday, UBS adjusted its outlook on ASX Limited (ASX:AU) (OTC: ASXFY) shares, reducing the price…

Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease

MADRID, June 14, 2024 (GLOBE NEWSWIRE) — Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing…

Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201 By Investing.com

“ No CRS, ICANS, infections or serious adverse events observed in either of the first two…